Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Authors
Choueiri, TLarkin, J
Oya, M
Thistlethwaite, Fiona C
Martignoni, M
Nathan, P
Powles, T
McDermott, D
Robbins, P
Chism, D
Cho, D
Atkins, M
Gordon, M
Gupta, S
Uemura, H
Tomita, Y
Compagnoni, A
Fowst, C
di Pietro, A
Rini, B
Affiliation
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USAIssue Date
2018-04
Metadata
Show full item recordAbstract
The combination of an immune checkpoint inhibitor and a VEGF pathway inhibitor to treat patients with advanced renal-cell carcinoma might increase the clinical benefit of these drugs compared with their use alone. Here, we report preliminary results for the combination of avelumab, an IgG1 monoclonal antibody against the programmed cell death protein ligand PD-L1, and axitinib, a VEGF receptor inhibitor approved for second-line treatment of advanced renal-cell carcinoma, in treatment-naive patients with advanced renal-cell carcinoma.Citation
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. 2018, 19(4): 451-460 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(18)30107-4PubMed ID
29530667Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(18)30107-4